Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)

被引：1
|
作者：
Tao, P. [1 ]
Wei, Y. [1 ]
Zhu, G. [1 ]
Zeng, Z. [2 ]
Lv, Z. [3 ]
Ma, J. [2 ]
Ye, X. [1 ]
Su, H. [1 ]
Xiao, K. [1 ]
Liao, J. [4 ]
Su, M. [1 ]
Yu, S. [1 ]
Long, L. [4 ]
Wang, J. [1 ]
Peng, N. [1 ]
Zhao, K. [1 ]
Han, C. [1 ]
Liao, X. [1 ]
Qin, W. [1 ]
Yang, C. [1 ]
机构：
[1] Guangxi Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, Nanning, Peoples R China
[2] Guangxi Med Univ, Dept Med Oncol, Affiliated Hosp 1, Nanning, Peoples R China
[3] Guangxi Med Univ, Dept Pathol, Affiliated Hosp 1, Nanning, Peoples R China
[4] Guangxi Med Univ, Dept Radiol, Affiliated Hosp 1, Nanning, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.766
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
187P
引用
收藏
页码：S1547 / S1548
页数：2
相关论文
共 23 条
  • [1] NEOADJUVANT CADONILIMAB ( PD-1/ CTLA-4 BISPECIFIC ANTIBODY) PLUS TRANSHEPATIC ARTERIAL INFUSION CHEMOTHERAPY ( HAIC) WITH FOLFOX FOR RESECTABLE MULTINODULAR CNLC Ib/ IIa HEPATOCELLULAR CARCINOMA
    Wei, Yonguang
    Zeng, Zhiming
    Zhu, Guangzhi
    Lv, Zili
    Peng, Tao
    HEPATOLOGY, 2023, 78 : S1861 - S1862
  • [2] Cadonilimab, a PD-1/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study
    Yilin Wang
    Shida Pan
    Jiahe Tian
    Jianing Wang
    Yingying Yu
    Siyu Wang
    Fengyi Li
    Luo Yang
    Xiaomeng Liu
    Yingjuan Shen
    Qin Qiu
    Junqing Luan
    Mengdie Jia
    Chuyue Xiong
    Xuanxuan Duan
    Fu-Sheng Wang
    Fanping Meng
    Cancer Immunology, Immunotherapy, 74 (6)
  • [3] Infusion-Related Reactions Induced by Cadonilimab (PD-1/CTLA-4 Bispecific Antibody): Seven Case Reports
    Liang, Weiting
    Guo, Zhijun
    Zhang, Yunhui
    Yang, Ning
    Guo, Chenchen
    Liu, Tao
    Huang, Hongbing
    Chen, Zhuojia
    CASE REPORTS IN ONCOLOGY, 2024, 17 (01): : 361 - 369
  • [4] Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus FLOT chemotherapy in locally advanced gastric/gastroesophageal junction cancer (GC/GEJC): A prospective, multi-center, phase II study
    Jiao, Zuoyi, Sr.
    Zhou, Huinian, Sr.
    Yu, Zyuaun, Sr.
    Long, Bo
    Huang, Zeping
    Zhao, Da
    Wei, Dengwen
    Zhao, Xiaonin
    Jiang, Zebin
    Yang, Xiaojun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Lenvatinib in combination with PD-1 inhibitor and hepatic arterial infusion chemotherapy (HAIC) for patients with potentially resectable hepatocellular carcinoma: A retrospective analysis.
    Dong, Wei
    Zhang, Songyan
    Huo, Zhuoni
    Lu, Junrong
    Liu, Haishi
    Wang, Ping
    Zhang, Yubao
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer
    Bolin Chen
    Wenxiu Yao
    Xingya Li
    Gen Lin
    Qian Chu
    Hailong Liu
    Yingying Du
    Jie Lin
    Huaxin Duan
    Huijuan Wang
    Zemin Xiao
    Hong Sun
    Liyu Liu
    Li Xu
    Yan Xu
    Fang Xu
    Yi Kong
    Xingxiang Pu
    Kang Li
    Qianzhi Wang
    Jia Li
    Baiyong Li
    Yu Xia
    Lin Wu
    British Journal of Cancer, 2024, 130 : 450 - 456
  • [7] A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer
    Chen, Bolin
    Yao, Wenxiu
    Li, Xingya
    Lin, Gen
    Chu, Qian
    Liu, Hailong
    Du, Yingying
    Lin, Jie
    Duan, Huaxin
    Wang, Huijuan
    Xiao, Zemin
    Sun, Hong
    Liu, Liyu
    Xu, Li
    Xu, Yan
    Xu, Fang
    Kong, Yi
    Pu, Xingxiang
    Li, Kang
    Wang, Qianzhi
    Li, Jia
    Li, Baiyong
    Xia, Yu
    Wu, Lin
    BRITISH JOURNAL OF CANCER, 2024, 130 (03) : 450 - 456
  • [8] Phase 2 study of AK104 (PD-1/CTLA-4 bispecific antibody) plus lenvatinib as first-line treatment of unresectable hepatocellular carcinoma.
    Bai, Li
    Sun, Meili
    Xu, Aibing
    Bai, Yuxian
    Wu, Jian
    Shao, Guoliang
    Song, Lijie
    Jin, Xiaoping
    Song, Weifeng
    Li, Baiyong
    Xia, Yu
    Jiao, Shunchang
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
    Xu, Q.
    Ying, J.
    Zhang, L.
    Li, J.
    Zeng, P.
    Yuan, X.
    Huang, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1550 - S1550
  • [10] An open, prospective, single arm, phase II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) with neoadjuvant chemotherapy in patients with advanced ovarian cancer: Interim analysis from the AK104-IIT-003 study
    Tang, Jie
    Tian, Wenfang
    Huang, Si
    Yang, Jun
    Yang, Hongying
    Zhang, Jieqing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
123